Moderna said new data obtained showed that the Covid vaccine was more than 90 percent effective against the virus six months after the second dose. In the statement made, it was stated that the vaccine was more than 95 percent effective against serious diseases until six months after the second dose.
The US pharmaceutical company Moderna announced new data on the Covid-19 vaccine. In the statement, it was stated that the Covid-19 vaccine was more than 90 percent effective in protecting against the virus and that it was more than 95 percent effective against serious diseases until six months after the second dose of the vaccine.
Stating that the new data obtained were obtained by examining more than 900 Covid-19 cases, 100 of which were severe, until April 9, Moderna said that the obtained preliminary results are the preliminary results, and will share updated data on the effectiveness and persistence of antibodies against asymptomatic infection throughout the year. told.
Moderna reportedly announced the new data she obtained after a study published in the New England Journal of Medicine showed that antibodies caused by the Moderna vaccine were still present six months after the second dose.
ONE STEP IS COMING TO FULL CONFIRMATION
The new data announced brought Moderna one step closer to getting full approval from the US drug agency for the Covid-19 vaccine.
It is stated that the vaccine, which has an emergency use permit for two months, will go through a more rigorous examination process in order to obtain full approval, and Moderna may start selling its vaccines directly to consumers and private companies.
After obtaining full approval, Moderna can begin to market the shots directly to consumers and sell them to individuals and private companies in the USA.
WORKS CONTINUE FOR 17 YEARS AND UNDER
While the Moderna vaccine is administered for people over the age of 18, the company continues to work for those aged 17 and under.
BioNTech – Pfizer recently updated the vaccine data and announced the effectiveness rate of the vaccine as 91.3 percent, according to the study conducted on 44 thousand people in November. In the statement, it was also stated that the vaccine provided protection against Covid-19 for at least six months. The vaccine’s effectiveness rate was previously announced as 95.3 percent.